Cerus Corporation (CERS)
| Market Cap | 515.09M |
| Revenue (ttm) | 188.32M |
| Net Income (ttm) | -42.78M |
| Shares Out | 177.62M |
| EPS (ttm) | -0.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,082,033 |
| Open | 2.83 |
| Previous Close | 2.82 |
| Day's Range | 2.77 - 2.93 |
| 52-Week Range | 2.36 - 5.95 |
| Beta | 0.97 |
| Analysts | Buy |
| Price Target | 7.91 (+172.76%) |
| Earnings Date | May 4, 2023 |
About CERS
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood ... [Read more]
Financial Performance
In 2022, Cerus's revenue was $188.32 million, an increase of 18.05% compared to the previous year's $159.52 million. Losses were -$42.78 million, -21.32% less than in 2021.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for CERS stock is "Buy." The 12-month stock price forecast is $7.91, which is an increase of 172.76% from the latest price.
News
Cerus Corporation Announces Record Fourth Quarter and Full-Year 2022 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2022.
Cerus Corporation to Release Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 28, 2023, after th...
Cerus Corporation to Participate in Upcoming Investor Conferences
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that the Company will participate in two upcoming investor conferences. William ‘Obi' Greenman, Cerus' president and ...
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2022 Product Revenue and Provides Business Update
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2022 and provided product revenue guidance for ful...
Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates
Cerus (CERS) delivered earnings and revenue surprises of 0% and 1.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cerus Corporation Announces Third Quarter Financial Results
CONCORD, Calif.
Cerus Corporation Announces Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate
CONCORD, Calif.
Cerus Corporation Announces Health Canada Approval for INTERCEPT Blood System for Platelets with Seven-Day Storage
CONCORD, Calif.
Cerus Corporation to Release Third Quarter 2022 Financial Results on November 3, 2022
CONCORD, Calif.
Cerus Corporation Announces Workshop and Abstracts at the 2022 AABB Annual Meeting
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2022 AABB Annual Meeting, taking place in Orlando, FL from Oc...
After Plunging 17.6% in 4 Weeks, Here's Why the Trend Might Reverse for Cerus (CERS)
Cerus (CERS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ear...
Down 20.4% in 4 Weeks, Here's Why Cerus (CERS) Looks Ripe for a Turnaround
Cerus (CERS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates cou...
Cerus Corporation Acknowledges Growing Monkeypox Outbreak and Public Health Emergency
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) acknowledges the U.S. Department of Health and Human Services' declaration of monkeypox as a national Public Health Emergency. Curren...
Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates
Cerus (CERS) delivered earnings and revenue surprises of 16.67% and 2.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cerus Corporation Announces Another Record Quarter and Reiterates Full Year 2022 Product Revenue Guidance Range
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2022. Recent developments and highlights include: Second quar...
Cerus Corporation to Release Second Quarter 2022 Financial Results on August 4, 2022
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2022 financial results will be released on Thursday, August 4, 2022, after the close of the s...
Cerus (CERS) Upgraded to Strong Buy: What Does It Mean for the Stock?
Cerus (CERS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cerus Corporation Announces Appointment of Hua Shan, MD, PhD to Board of Directors
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced the appointment of Hua Shan, MD, PhD, Professor of Pathology and Medical Director, Transfusion Medicine Service at St...
Wall Street Analysts See an 89% Upside in Cerus (CERS): Can the Stock Really Move This High?
The consensus price target hints at an 88.6% upside potential for Cerus (CERS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r...
Cerus Corporation Celebrates World Blood Donor Day 2022
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2022. For over 15 years, World Blood Donor Day has helped served as an ...
Does Cerus (CERS) Have the Potential to Rally 88% as Wall Street Analysts Expect?
The mean of analysts' price targets for Cerus (CERS) points to an 87.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts ...
Does Cerus (CERS) Have the Potential to Rally 89% as Wall Street Analysts Expect?
The mean of analysts' price targets for Cerus (CERS) points to an 89.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts ...
Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates
Cerus (CERS) delivered earnings and revenue surprises of 30% and 2.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cerus Corporation Announces First Quarter 2022 Financial Results and Increases Full Year 2022 Product Revenue Guidance Range
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2022. Recent developments and highlights include: First quart...
Cerus Corporation Announces New Manufacturing and Supply Agreement With Fresenius Kabi For INTERCEPT Blood System Sets
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that it has signed a ten-year agreement with Fresenius Kabi for the production of INTERCEPT Blood System sets. This n...